 |
Next Article 
The Journal of Neuroscience, 2001, 21:RC141:1-4
RAPID COMMUNICATION
Cocaine and Amphetamine Increase Extracellular Dopamine in
the Nucleus Accumbens of Mice Lacking the Dopamine Transporter
Gene
Ezio
Carboni1,
Cécile
Spielewoy2,
Cinzia
Vacca1,
Marika
Nosten-Bertrand2,
Bruno
Giros2, and
Gaetano
Di
Chiara1
1 Department of Toxicology and Consiglio Nazionale
delle Ricerche Center for Neuropharmacology, University of
Cagliari, 09126 Cagliari, Italy, and 2 Neurobiology and
Psychiatry Faculté de Medicine de Creteil, 94000 Creteil, France
 |
ABSTRACT |
Behavioral and biochemical studies suggest that dopamine (DA) plays
a role in the reinforcing and addictive properties of drugs of abuse.
Recently, this hypothesis has been challenged on the basis of the
observation that, in mice genetically lacking the plasma membrane
dopamine transporter [DAT-knock out (DAT-KO)], cocaine maintained its
reinforcing properties of being self-administered and inducing place
preference, despite the failure to increase extracellular dopamine in
the dorsal striatum. Here we report that, in DAT-KO mice, cocaine and
amphetamine increase dialysate dopamine in the medial part of the
nucleus accumbens. Moreover, reboxetine, a specific blocker of the
noradrenaline transporter, increased DA in the nucleus accumbens of
DAT-KO but not of wild-type mice; in contrast, GBR 12909, a specific
blocker of the dopamine transporter, increased dialysate dopamine in
the nucleus accumbens of wild-type but not of DAT-KO mice. These
observations provide an explanation for the persistence of cocaine
reinforcement in DAT-KO mice and support the hypothesis of a primary
role of nucleus accumbens dopamine in drug reinforcement.
Key words:
dopamine; nucleus accumbens; DAT-knock-out mice; cocaine; amphetamine; reboxetine
 |
INTRODUCTION |
Cocaine
and amphetamine psychostimulants are abused by humans (Johanson and
Schuster, 1995 ) and self-administered by primates (Bergman et al.,
1989 ) and rats (Richardson and Roberts, 1996 ). Among brain monoamines,
dopamine (DA) has been attributed an important role in the reinforcing
properties of drugs of abuse and in particular of cocaine and
amphetamine (Wise and Bozarth, 1987 ; Koob, 1992 ; Di Chiara et al.,
1993 ; Di Chiara, 1995 ). These psychostimulants increase extracellular
DA by blocking the DA transporter (DAT) on DA nerve terminals (cocaine)
or by promoting the nonexocytotic release of DA (amphetamine).
Recently, the DA hypothesis of the reinforcing properties of cocaine
has been challenged on the basis of the report that, in mice
genetically lacking DAT [DAT-knock-out (KO)] (Giros et al., 1996 ),
cocaine was self-administered but failed to increase extracellular DA
in the caudate putamen (CPu), (Rocha et al., 1998 ; Sora et al., 1998 ).
Cocaine however, like most drugs of abuse, increases DA preferentially
in the nucleus accumbens (NAc) compared with the dorsal CPu, and this
property has been hypothesized to be related to the reinforcing
properties of drugs of abuse (Di Chiara and Imperato, 1988 ; Carboni et
al., 1989 ; Barrot et al., 2000 ). In view of this, failure of cocaine to
increase extracellular DA in the caudate putamen of DAT-KO mice is not
incompatible with the hypothesis of a role of DA in the reinforcing
effects of cocaine. In fact, although ineffective in the CPu, cocaine
might still increase extracellular DA in the NAc of DAT-KO mice. To
test this possibility, we studied by brain microdialysis the effect of
cocaine and amphetamine on extracellular DA in the NAc of DAT-KO
compared with wild-type mice.
 |
MATERIALS AND METHODS |
Animals. Homozygous
DAT / mice were obtained by homologous
recombination as described previously (Giros et al., 1996 ). These mice
were then backcrossed for more than 15 generations on a C57BL/6 background. DAT / and wild-type
DAT+/+ littermates were obtained from the
mating of DAT+/ mice. The genotype of
the mice was determined by PCR analysis as follows. Genomic DNA (50 ng) from tail biopsies was amplified with primers DAT-1
(CCCGTCTACCCATGAGTAAAA), DAT-2 (CTCCACCTTCCTAGCACTAAC), and NEO2
(TGACCGCTTCCTCGTGC), generating a 870 bp product (DAT-1/NEO2) for the
recombined DAT gene and a 580 bp product (DAT-1/DAT-2) for the
wild-type DAT gene. After weaning, mice were housed two to four
per cage and maintained under standard housing conditions with food and
water available ad libitum. All mice used were 8-12 weeks
old, drug naïve, and were only used in one test. All animal experimentation was conducted in accordance with the guidelines for
care and use of experimental animals of the European Economic Community
(86/809; DL 27.01.92, Number 116).
Probe preparation. Concentric dialysis probes were prepared
with a 7 mm piece of AN 69 (sodium methallyl sulfate copolymer) dialysis fiber (310 µm outer diameter, 220 µm inner diameter; Hospal, Dasco, Italy), sealed at one end with a drop of epoxy glue. Two
4-cm-long pieces of fused silica (Composite Metal Services, Worcester,
UK) tubing were introduced in the dialysis fiber, taking care to
have the inlet reaching the lower end and the outlet reaching the
higher end of the dialyzing portion (1.0 mm) of the fiber. The inlet
and the outlet were then sealed to the fiber and to a 18 mm piece of
stainless steel (obtained from a 24 gauge needle) that were then
inserted into a piece of 200 µl micropipette tip 6-mm-long and glued
to it. The fiber was covered with a thin layer of epoxy glue, except
for the dialyzing part. The probe was left to dry for 24 hr (Di Chiara,
1990 ; Di Chiara et al., 1996 ).
Surgery and experiments. Mice anesthetized with chloral
hydrate (400 mg/kg, i.p.) were placed in a stereotaxic apparatus. The
skull was exposed, and a small hole was drilled on the right side. The
head position was adjusted so that bregma and lambda had the same
height. The probe was implanted vertically in the medial accumbens
(anterior, 1.2 mm; lateral, 0.6 mm; vertical, 5.2 mm from the bregma)
or in the CPu (anterior, 0.0; lateral, 1.8 mm; vertical, 4 mm from the
bregma), according to the atlas of Franklin and Paxinos (1997) and then
fixed on the skull with dental cement. Mice were housed in a
transparent plastic (Plexiglas) hemisphere, closed with a top
hemisphere, with food and water available. Experiments were performed
on freely moving mice 48 hr after probe implant. Ringer's solution
(147 mM NaCl, 2.2 mM CaCl2, and 4 mM KCl) was
pumped through the dialysis probe at constant rate of 1 µl/min.
Samples were taken every 20 min and analyzed.
Analytical procedure. Dialysate samples (20 µl) were
injected without any purification into an HPLC apparatus equipped with reverse-phase column (LC-18 DB; Supelco, Bellefonte, PA) and a coulometric detector (Coulochem II; ESA Inc., Bedford, MA) to quantify
DA. The first electrode was set at +130 mV and the second electrode at
125 mV. The composition of the mobile phase was 50 mM Na H2
PO4, 5 mM
Na2HPO4, 0.1 mM Na2EDTA, 0.5 mM octyl sodium sulfate, and 15% (vol/vol)
methanol, pH 5.5. The mobile phase was pumped with an LKB 2150 pump at
a flow rate of 1.0 ml/min. The sensitivity of the assay allowed for the
detection of 5 fmol of DA.
Histology. At the end of the experiment, mice were
anesthetized and transcardially perfused with 20 ml of saline (0.9%
NaCl) and 20 ml of formaldehyde (10%). The probes were removed, and brains were cut on a vibratome in serial coronal slices oriented according the atlas of Franklin and Paxinos (1997) . The position of the
probe was ascertained by observation under stereomicroscope (10-20
magnification) and comparison with corresponding levels of the atlas of
Franklin and Paxinos (1997) . Results from mice implanted incorrectly
were discarded.
Drugs. Cocaine HCl and amphetamine sulfate were obtained
from SALARS (Como, Italy). GBR 12909 was a gift from Novo A/S
(Bagsveerd, Denmark). Reboxetine was a gift from Pharmacia Upjohn
(Milan, Italy).
Statistics. Statistical analysis was performed by Statistica
(StatSoft Inc., Tulsa, OK). Three-way ANOVA for repeated
measures (time points) was applied to the data expressed as
percent of basal DA concentration obtained from the serial
assays of DA after each treatment. Results from treatments showing
significant overall changes were subjected to post hoc Tukey
test with significance for p < 0.05. Basal values were
the means of three consecutive samples differing <10%. Each implanted
mouse was challenged with a single dose of the test drug only once.
 |
RESULTS |
Basal dialysate DA from the NAc of wild-type and DAT-KO mice were
46.33 ± 6.74 and 192 ± 28 fmol/20 µl, respectively
(t = 5.31; df = 46; p < 0.0001). Basal dialysate DA from the CPu of wild-type and DAT-KO mice
were 38.8 ± 5.4 and 161 ± 31 fmol/20 µl, respectively
(t = 3.88; df = 16; p < 0.005).
Cocaine (20 mg/kg, i.p.) and amphetamine (5 and 2 mg/kg, i.p.) increase
dialysate DA in the NAc of both DAT-KO and wild-type mice (Figs.
lA,
2A,B
respectively). The maximal increase of DA elicited by cocaine or by
amphetamine in the NAc of DAT-KO mice did not differ significantly from
that of wild-type mice. Three-way ANOVA of the results shown in Figure
1A revealed a significant effect of treatment
(F(1,15) = 15.89; p < 0.005) and no effect of gene patrimony
(F(1,15) = 1.32; p = 0.26). The results in Figure 2, A and B, revealed
a significant effect of treatment
(F(1,14) = 29.44; p < 0.0005; and F(1,13) = 15.85;
p < 0.005, respectively) and no effect of gene
patrimony (F(1,14) = 0.3;
p = 0.59; and F(1,13) = 1.18; p = 0.29, respectively).

View larger version (25K):
[in this window]
[in a new window]
|
Figure 1.
Effect of cocaine (20 mg/kg, i.p.) on dopamine
concentration in dialysate obtained by in vivo
microdialysis from the NAc (A) and the CPu
(B) in both DAT-KO ( / ) and wild-type (+/+)
mice. Each point is the mean ± SEM of at least
three to six determinations. #p < 0.05 from basal
values concentration; *p < 0.05 from the
corresponding time point of vehicle group.
|
|

View larger version (28K):
[in this window]
[in a new window]
|
Figure 2.
Effect of amphetamine (2 and 5 mg/kg, i.p.;
A and B, respectively) on dopamine
concentration in dialysate obtained by in vivo
microdialysis from the NAc in both DAT-KO ( / ) and wild-type (+/+)
mice. Each point is the mean ± SEM of at least
three to six determinations. #p < 0.05 from basal
values concentration; *p < 0.05 from the
corresponding time point of vehicle group.
|
|
Figure 1B shows that cocaine increased dialysate DA
in the CPu of wild-type but not DAT-KO mice. Three-way ANOVA revealed a
significant effect of treatment
(F(1,8) = 40.8; p < 0.001), gene patrimony (F(1,8) = 26.35; p < 0.001), and interaction
(F(9,72) = 10.46;
p < 0.0001). Figure
3A shows that GBR 12909 (10 mg/kg, i.p.; A) increased significantly dialysate DA in the
NAc of wild-type mice but not DAT-KO mice, whereas reboxetine (20 mg/kg, i.p.; B) increased significantly dialysate DA in
DAT-KO but not wild-type mice. Three-way ANOVA of the results shown in
A revealed a significant effect of treatment
(F(1,10) = 86.29; p < 0.0001), gene patrimony (F(1,10) = 129.8; p < 0.0001), and interaction
(F(9,90) = 18.58; p < 0.0001). The results in B revealed a significant effect of treatment (F(1,17) = 7.61;
p < 0.05) and gene patrimony
(F(1,17) = 8.97; p < 0.01). Fluoxetine (10 mg/kg, i.p.) did not modify dialysate DA in the
NAc of either wild-type and KO-DAT mice
(F(1,13) = 0.75; p = 0.40).

View larger version (25K):
[in this window]
[in a new window]
|
Figure 3.
Effect of GBR 12909 (10 mg/kg i.p.;
A) and reboxetine (20 mg/kg, i.p.; B) on
dopamine concentration in dialysate obtained by in vivo
microdialysis from the NAc in both DAT-KO ( / ) and wild-type (+/+)
mice. Each point is the mean ± SEM of at least
three determinations. #p < 0.05 from basal values
concentration; *p < 0.05 from the corresponding
time point of vehicle group.
|
|
 |
DISCUSSION |
This study shows that the psychostimulants cocaine and amphetamine
increase dialysate dopamine in the NAc of both DAT-KO and wild-type
mice. In agreement with previous studies (Rocha et al., 1998 ), no
significant change in dialysate DA was observed in the CPu of DAT-KO
mice after cocaine, whereas basal dialysate DA in DAT-KO mice was
approximately fourfold higher than in wild-type mice. In contrast to
cocaine and amphetamine, GBR 12909, a specific blocker of DAT
(Andersen, 1989 ), failed to increase dialysate DA in the NAc of
DAT-KO at doses that are fully effective in wild-type mice and in rats
(Carboni et al. 2000 ). Cocaine and amphetamine, unlike GBR 12909, also
block the norepinephrine transporter (NET), as well as the
serotonin transporter (SERT). However, a role of SERT blockade alone in
the psychostimulant-induced increase of DA in NAc of DAT-KO mice is
made unlikely by the observation that fluoxetine, a potent SERT
inhibitor, failed to increase DA in the NAc of DAT-KO mice (see
Results). This in turn is consistent with the fact that DA is not a
good substrate for SERT (Raiteri et al., 1977 ). A better candidate as a
substrate for psychostimulant-induced increase of DA in the NAc of
DAT-KO mice is NET, reportedly even more efficient than DAT in taking
up DA (Raiteri et al., 1977 ; Giros and Caron, 1993 ). Indeed, in the rat
prefrontal cortex, in which norepinephrine (NE) innervation
prevails over DA innervation, DA has been reported to be cleared from
the extracellular space by NET rather than by DAT (Carboni et al.,
1990 ; Tanda et al., 1997 ). Although NET blockade in the medial NAc does
not seem to contribute to a significant extent to the clearance of DA
from the extracellular space (Tanda et al., 1997 ), the NAc shell to which the medial NAc corresponds receives in the rat a consistent NE
projection (Berridge et al., 1997 ). We speculated that, in the DAT-KO
mice, the NET expressed by NE terminals of the NAc could, because
of the absence of DAT, act as an alternative site for DA
clearance from the extracellular compartment.
To test this hypothesis, we investigated the effect of the specific NET
blocker reboxetine (Wong et al. 2000 ) on extracellular DA in the medial
NAc of DAT-KO mice. Results show that reboxetine increased DA in the
NAc of DAT-KO but not of wild-type mice. It is notable that the maximal
increase of dialysate DA after reboxetine in the NAc of DAT-KO mice was
not different from that obtained after cocaine in the same area
(F(1,10) = 0.678; p = 0.429). Like cocaine and amphetamine, reboxetine failed to increase DA
in the CPu of DAT-KO mice (data not shown). These observations suggest that cocaine and amphetamine increase DA in the medial NAc of DA-KO
mice by blocking NET. This mechanism appears to take place in the
DAT-KO and not in wild-type mice as a result of diversion of DA
reuptake to NET in the absence of DAT. In turn, the ability of
reboxetine and psychostimulants to increase DA in the medial NAc but
not in the CPu of DAT-KO mice is consistent with the presence of
NET-containing terminals in the caudal half of the accumbens shell but
not in the caudate putamen (Berridge et al., 1997 ).
The present observations, although offering an explanation for the
persistence of cocaine reinforcement in DAT-KO mice, predict that NET
blockade would be reinforcing specifically in DAT-KO mice. If this
prediction will hold true, not only the DA hypothesis of drug
reinforcement will be confirmed but also that of a specific role of NAc
DA (Wise and Bozarth, 1987 ; Di Chiara and Imperato, 1988 ; Koob, 1992 ;
Di Chiara, 1995 ) will receive a strong support. From a more general
viewpoint, the present study provides a remarkable example of
compensation for the influence of a complete genetic deletion of the
substrate of a central drug effect (DAT).
 |
FOOTNOTES |
Received Nov. 29, 2000; revised Feb. 6, 2001; accepted Feb. 12, 2001.
This work was supported by funds from Consiglio Nazionale delle
Ricerche and Ministero della Ricerca Scientifica e Tecnologica.
Correspondence should be addressed to Dr. Gaetano Di Chiara, Department
of Toxicology, University of Cagliari, Viale Diaz 182, 09126 Cagliari,
Italy. E-mail: diptoss{at}tin.it.
This article is published in
The Journal of Neuroscience, Rapid Communications Section,
which publishes brief, peer-reviewed papers online, not in print. Rapid
Communications are posted online approximately one month earlier than
they would appear if printed. They are listed in the Table of Contents
of the next open issue of JNeurosci. Cite this article as:
JNeurosci, 2001, 21:RC141 (1-4). The
publication date is the date of posting online at
www.jneurosci.org.
 |
REFERENCES |
-
Andersen PH
(1989)
The dopamine uptake inhibitor GBR 12909.
Eur J Pharmacol
32:493-504.
-
Barrot M,
Marinelli M,
Abrous DN,
Rouge-Pont F,
Le Moal M,
Piazza PV
(2000)
The dopaminergic hyper-responsiveness of the shell of the nucleus accumbens is hormone-dependent.
Eur J Neurosci
12:973-979.
-
Bergman J,
Madras BK,
Johnson SE,
Spealman RD
(1989)
Effects of cocaine and related drugs of abuse in nonhuman primates. III. Self-administration by squirrel monkeys.
J Pharmacol Exp Ther
251:150-155.
-
Berridge CW,
Stratford TL,
Foote SL,
Kelley AE
(1997)
Distribution of dopamine b-hydroxylase-like immunoreactivity fibers within the shell subregion of the nucleus accumbens.
Synapse
27:230-241.
-
Carboni E,
Imperato A,
Perezzani L,
Di Chiara G
(1989)
Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats.
Neuroscience
28:653-661.
-
Carboni E,
Tanda G,
Frau R,
Di Chiara G
(1990)
Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals.
J Neurochem
55:1067-1090.
-
Carboni E,
Silvagni A,
Rolando MPT,
Di Chiara G
(2000)
Stimulation of in vivo dopamine transmission in the bed nucleus of stria terminalis by reinforcing drugs.
J Neurosci
20:RC102(1-5).
-
Di Chiara G
(1990)
In vivo brain dialysis of neurotransmitters.
Trends Pharmacol Sci
11:116-121.
-
Di Chiara G
(1995)
The role of dopamine in drug abuse viewed from the perspective of its role in motivation.
Drug Alcohol Depend
38:95-137.
-
Di Chiara G,
Imperato A
(1988)
Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.
Proc Natl Acad Sci USA
85:5274-5278.
-
Di Chiara G,
Tanda G,
Frau R,
Carboni E
(1993)
On the preferentially release of dopamine in the nucleus accumbens by amphetamine: further evidence obtained by vertically implanted concentric dialysis probes.
Psychoparmacology
112:398-402.
-
Di Chiara G,
Tanda G,
Carboni E
(1996)
Estimation of in vivo neurotransmitter release by brain microdialysis: the issue of validity.
Behav Pharmacol
7:640-657.
-
Franklin KBJ,
Paxinos G
(1997)
In: The mouse brain in stereotaxic coordinates. San Diego: Academic.
-
Giros B,
Caron MG
(1993)
Molecular characterization of the dopamine transporter.
Trends Pharmacol Sci
14:43-49.
-
Giros B,
Jaber M,
Jones SR,
Wightman RM,
Caron MG
(1996)
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter.
Nature
379:606-612.
-
Johanson CE,
Schuster RS
(1995)
Cocaine.
In: Psychopharmacology: the fourth generation of progress (Bloom FE,
Kupfer DJ,
eds), pp 1685-1697. New York: Raven.
-
Koob GF
(1992)
Drugs of abuse: anatomy, pharmacology and function of reward pathways.
Trends Neurosci
13:177-184.
-
Raiteri M,
Del Carmine R,
Bertolini A,
Levi G
(1977)
Effects of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine.
Eur J Pharmacol
41:133-143.
-
Richardson NR,
Roberts DC
(1996)
Progressive ratio schedules in drug self-administration study in rats: a method to evaluate reinforcing efficacy.
J Neurosci Methods
66:1-11.
-
Rocha BA,
Fumagalli F,
Gainetdinov RR,
Jones SR,
Ator R,
Giros B,
Miller GW,
Caron MG
(1998)
Cocaine self-administration in dopamine-transporter knockout mice.
Nat Neurosci
1:132-137.
-
Sora I,
Wichems C,
Takahasci N,
Li X-F,
Zeng Z,
Revay R,
Lesch KL,
Murphy DL,
Uhl GR
(1998)
Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice.
Proc Natl Acad Sci USA
9:7699-7704.
-
Tanda G,
Pontieri FE,
Frau R,
Di Chiara G
(1997)
Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine.
Eur J Neurosci
9:2077-2085.
-
Wise RA,
Bozarth MA
(1987)
A psychomotor stimulant theory of addiction.
Psychol Rev
94:469-492.
-
Wong EH,
Sonders MS,
Amara SG,
Tinholt PM,
Piercey MF,
Hoffmann WP,
Hyslop DK,
Franklin S,
Porsolt RD,
Bonsignori A,
Carfagna N,
McArthur RA
(2000)
Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.
Biol Psychiatry
47:818-829.
Copyright © Society for Neuroscience 0270-6474//$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
E. S. Vizi, G. Zsilla, M. G. Caron, and J. P. Kiss
Uptake and Release of Norepinephrine by Serotonergic Terminals in Norepinephrine Transporter Knock-Out Mice: Implications for the Action of Selective Serotonin Reuptake Inhibitors
J. Neurosci.,
September 8, 2004;
24(36):
7888 - 7894.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Auclair, S. Cotecchia, J. Glowinski, and J.-P. Tassin
D-Amphetamine Fails to Increase Extracellular Dopamine Levels in Mice Lacking alpha 1b-Adrenergic Receptors: Relationship between Functional and Nonfunctional Dopamine Release
J. Neurosci.,
November 1, 2002;
22(21):
9150 - 9154.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|